AbbVie hepatitis C drugs show high cure rate ahead of filing
This article was originally published in Scrip
AbbVie said its all-oral hepatitis C regimen cleared the virus in most patients in a late-stage study that will be used as part of the company’s approval application next year.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.